Cagrilintide Research: Long-Acting Amylin Analog and the CagriSema Pipeline

Cagrilintide is a long-acting synthetic analog of amylin, the satiety hormone co-secreted with insulin by pancreatic beta cells. The compound's research profile is unusual within the obesity-pharmacotherapy landscape: rather than another receptor permutation of incretin biology (GLP-1, GIP, glucagon), cagrilintide opens an entirely different receptor pathway — amylin signalling via the calcitonin-receptor family. This article walks through cagrilintide's mechanism, the published monotherapy and combination evidence, and where the compound sits in the next-generation obesity pipeline.

Amylin physiology: a satiety hormone outside incretin biology

Amylin is a 37-amino-acid peptide hormone co-released with insulin from pancreatic beta cells in response to nutrient ingestion. Its canonical effects on glucose and weight metabolism include:

• Slowed gastric emptying — reducing the rate of nutrient delivery to the small intestine
• Suppressed inappropriate glucagon secretion — reducing hepatic glucose output postprandially
• Central satiety effects — direct action on hindbrain area postrema neurons that integrate satiety signals

Amylin signals through a heteromeric receptor complex: the calcitonin receptor combined with receptor-activity-modifying proteins (RAMPs). This is mechanistically distinct from GLP-1, GIP, and glucagon receptor signalling — separate receptor family, separate downstream signalling cascade.

The Panou 2024 review (Expert Rev Clin Pharmacol) ³ summarises the broader amylin-class pharmacology and the evolution of amylin-pathway research from the short-acting pramlintide (FDA-approved 2005 for diabetes) to the current long-acting analog programmes including cagrilintide.

Cagrilintide: the long-acting amylin analog

Cagrilintide is engineered specifically to address pramlintide's clinical limitations. Pramlintide has a short circulating half-life that requires multiple daily injections, which limited its uptake clinically. Cagrilintide's engineered modifications extend the circulating half-life to support once-weekly dosing — the same dosing cadence as the leading GLP-1 and GIP/GLP-1 compounds.

The receptor pharmacology preserves amylin's satiety-relevant effects: gastric emptying delay, central satiety signalling, postprandial glucagon suppression. The combination of mechanism plus weekly dosing makes cagrilintide viable as both a monotherapy candidate and a combination partner with incretin-class compounds.

Lau 2021 — monotherapy Phase 2 dose-finding

Lau DCW and colleagues' 2021 Lancet paper ¹ reported the canonical cagrilintide monotherapy Phase 2 trial. Design: 706 adults with overweight or obesity (BMI ≥27) without type-2 diabetes randomised to cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg weekly, liraglutide 3 mg daily, or placebo. Duration: 26 weeks.

Results: weight loss was dose-dependent. At week 26, mean body-weight changes from baseline were approximately -3.0% (placebo), -6.0% (cagrilintide 0.3 mg), and progressing through the dose range to -10.8% at the 4.5 mg dose. The liraglutide 3 mg active-control arm produced approximately -9.0%.

The interpretive headline: cagrilintide 4.5 mg monotherapy at 26 weeks produced weight loss comparable to or slightly exceeding liraglutide 3 mg daily monotherapy. Both fell below the magnitudes reported for semaglutide 2.4 mg monotherapy in STEP-1 (14.9% at 68 weeks). Cagrilintide is not framed as a monotherapy challenger to semaglutide; its programme value is in combination.

Gastrointestinal tolerability was consistent with the amylin-class profile — nausea was the most common adverse event, generally mild-to-moderate and tending to resolve with continued treatment. The trial supported progression to Phase 3 monotherapy programmes and to the CagriSema combination programme.

Enebo 2021 — CagriSema Phase 1b combination

Enebo LB and colleagues' 2021 Lancet paper ² reported the Phase 1b combination trial that anchored the CagriSema programme. Design: 96 adults with overweight or obesity randomised to concomitant administration of multiple cagrilintide dose levels with semaglutide 2.4 mg weekly. Duration: 20 weeks.

Results: body weight reduced approximately 15.7% with the CagriSema combination at week 20 — a magnitude that compares favourably to semaglutide 2.4 mg monotherapy at similar timepoints. The Phase 1b primary endpoints were safety, tolerability, and pharmacokinetic compatibility rather than weight loss as primary, but the secondary efficacy signal was the result that drove the programme into larger trials.

The mechanism reasoning is straightforward: GLP-1 receptor agonism (semaglutide) and amylin/calcitonin receptor agonism (cagrilintide) enter satiety and glucose-control pathways from different upstream receptors. The empirical Phase 1b weight-loss magnitude is consistent with mechanism-complementarity rather than receptor-pathway redundancy.

Position in the next-generation obesity pipeline

The current obesity-pharmacotherapy pipeline beyond GLP-1 monotherapy includes several distinct mechanism strategies, each targeting larger weight-loss ceilings than semaglutide 2.4 mg monotherapy:

• Dual GIP/GLP-1 receptor agonism in a single molecule: tirzepatide (Phase 3 mature, SURMOUNT-1 20.9% weight loss at 15 mg). See the Tirzepatide clinical pharmacology article.
• Triple GIP/GLP-1/glucagon receptor agonism in a single molecule: retatrutide (Phase 2). See the Retatrutide deep-dive.
• Two-molecule combinations across mechanism families: CagriSema (cagrilintide + semaglutide). Phase 3 programmes ongoing at publication time.
• Amylin analogs in further combinations beyond CagriSema specifically. The Panou 2024 review highlights this as a strategic research direction.

Each strategy addresses the same underlying question (how to extend the weight-loss ceiling beyond GLP-1 monotherapy) with mechanism-distinct approaches. The strategies are not mutually exclusive — amylin combinations with multi-receptor incretin agonists are plausible future-generation research directions.

What is settled vs. exploratory

Settled:

• Cagrilintide monotherapy produces dose-dependent weight loss in obesity without diabetes (Lau 2021)
• The CagriSema combination produces weight loss exceeding semaglutide 2.4 mg monotherapy at comparable timepoints in Phase 1b data (Enebo 2021)
• Amylin signalling is mechanism-complementary rather than redundant with GLP-1 signalling
• Gastrointestinal tolerability of cagrilintide is consistent with the broader amylin-class profile

Exploratory:

• Phase 3 monotherapy and CagriSema efficacy outcomes (trials ongoing at publication time)
• Long-term weight-loss maintenance beyond the published trial windows
• Cardiovascular outcomes — no dedicated CVOT yet
• Effects in T2DM populations (existing trials enrolled non-diabetic obese/overweight)
• Combination with non-incretin classes (e.g., amylin + SGLT2, amylin + MC4R agonists)

For research-protocol selection

For research questions on amylin-pathway-specific weight-loss effects: cagrilintide monotherapy at the 4.5 mg dose is the closest published reference (Lau 2021).

For research questions on combination weight-loss strategies with mechanism complementarity beyond single-molecule multi-receptor agonism: CagriSema is the closest published reference (Enebo 2021).

For research questions on the broader incretin-class evolution including position of amylin analogs: the Panou 2024 review is the appropriate landscape reference (Expert Rev Clin Pharmacol).

For tirzepatide-context comparison see the Tirzepatide clinical pharmacology article. For semaglutide-context comparison see the Semaglutide vs Tirzepatide trials article. For retatrutide and the triple-agonist strategy see the Retatrutide research article.